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Abstract 
Background: The aim was to evaluate the characteristics and cardiovascular complications of a large Belgian cohort 
of adults diagnosed with type 2 diabetes (T2DM) <45 years.
Methods: Retrospective analysis of 886 patients diagnosed with T2DM <45 years and 933 T2DM patients diagnosed 
at the age between 60 and 70 years. To compare variables between groups, the independent t test or paired t test 
was used for normally distributed continuous variables, the Mann–Whitney’s U-test for non-normally distributed con-
tinuous variables and the Chi squared test or McNemar test for categorical variables. Multivariable logistic regression 
was used to adjust for confounders.
Results: In the young-onset T2DM cohort, the age at diagnosis was 37.3 ± 6.4 years, 44.1% of patients were female 
and 12.1% were from an ethnic minority (EM) background. At last visit, age of patients was 57.3 ± 12.5 years with a 
diabetes duration of 20.5 ± 11.8 years and a mean HbA1c of 7.3% ± 1.3 (56 mmol/mol ± 14). Of all patients, 56.8% 
were obese, 49.9% were hypertensive, 34.1% did not reach the LDL cholesterol target and 20.1% had a cardiac event 
by time of last visit. Compared to women, men had a higher HbA1c [7.3% ± 1.4 (56 mmol/mol ± 15) vs. 7.1% ± 1.2 
(54 mmol/mol ± 13), p = 0.021] and a significantly higher rate of cardiac events, even after adjustment for confound-
ers (24.3 vs. 14.8%, p = 0.010). Compared to Caucasians, EM patients were younger at diagnosis (35.4 ± 6.8 years vs. 
37.6 ± 6.2 years, p = 0.001) and were less often obese (43.3 vs. 55.6%, p = 0.007). Compared to the first visit, glycemic 
control improved [7.3% ± 1.3 (56 mmol/mol ± 14) vs. 7.9% ± 1.7 (62 mmol/mol ± 19), p < 0.0001] by the time of the 
last visit. Compared to the older-onset T2DM cohort, young-onset T2DM patients showed a higher HbA1c [7.3 ± 1.3% 
(56 mmol/mol ± 14) vs. 6.9 ± 1.0% (51 mmol/mol ± 11), p = <0.0001] and a higher BMI (31.2 ± 5.8 vs. 29.6 ± 5.5 kg/
m2, p = <0.0001) at last contact. When adjusted for age, diabetes duration, HbA1c and cardiovascular risk factors, 
there was no difference in cardiovascular events between the two cohorts.
Conclusions: A diagnosis of T2DM <45 years has an important impact on patients’ lives. Prevention measures are 
essential, but also specific attention to this high-risk group is needed for them to better achieve their therapeutic 
targets.
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Background
The incidence of young-onset type 2 diabetes (T2DM) 
is increasing worldwide and is strongly associated with 
the rise of obesity [1]. In the past, T2DM was considered 
a disease of older adults, but we are now also seeing the 
condition in children, adolescents and young adults [2, 
3]. Most evidence for an epidemic of young-onset T2DM 
comes from studies in the USA and Asia (particularly 
Japan) [4]. The ‘SEARCH for Diabetes in Youth study’ in 
the USA has reported incidence and prevalence rates of 
3.7–19/100.000 per year and 0.18–1.06/1.000 respectively, 
with higher rates seen in black and other ethnic minority 
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groups [5, 6]. More importantly, studies show that the 
prevalence is increasing over time [7]. Data from Euro-
pean populations are more limited and most data have 
been retrieved from pediatric care units (<17 years). Data 
from large diabetes centers in Sheffield and Leicester in 
the UK have shown that about 20% of adults with diabe-
tes diagnosed before the age of 40 years have T2DM [8, 
9]. The definition of young-onset T2DM remains variable. 
Generally, subjects are classified as young-onset T2DM if 
they were diagnosed with T2DM <45 years. This cut-off 
point has been selected for three reasons. Firstly, 45 years 
is the age the American Diabetes Association currently 
recommends for T2DM screening in adults. Secondly, 
the hazard of developing a myocardial infarction is four-
fold higher in T2DM diagnosed  <45  years compared to 
T2DM diagnosed >45 years [10]. Thirdly, using a cut-off 
point <45 years will include women of childbearing age, a 
cohort that requires special consideration [3].
Despite the younger age, recent data report that young-
onset T2DM patients have a more severe phenotype, 
a more adverse cardiovascular risk profile and a poorer 
glycemic control even with a higher use of insulin ther-
apy [10]. As a result, young-onset T2DM patients are at 
a high lifetime risk for the development of micro-and 
macrovascular complications [7]. However, few stud-
ies have evaluated the long-term risk for cardiovascular 
complications in European young-onset T2DM patients. 
We therefore performed a retrospective study of patients 
diagnosed with T2DM  <45  years attending our univer-
sity hospital between 2004 and 2014. We hypothesized 
that patients with young-onset T2DM have a high rate of 
cardiovascular complications despite a rather young age. 
We evaluated the general characteristics, cardiovascular 
risk factors, micro- and macrovascular complications 
and management strategies over time in a large Belgian 
young-onset T2DM cohort. Moreover, we compared the 
general characteristics of this population with a cohort of 
T2DM patients diagnosed between 60 and 70 years.
Methods
We performed a retrospective analysis of the electronic 
medical files of all patients who attended our center at 
the University Hospital UZ Leuven in Belgium between 
01-01-2004 and 31-12-2014 and who had the diagno-
sis of T2DM  <45  years. The study was approved by the 
Institutional Review Board of UZ Leuven (S58334) and 
conducted according to the principles expressed in the 
Declaration of Helsinki. Due to the retrospective nature 
of the study there was no need for informed consent from 
the participants (the data were analyzed anonymously) as 
in compliance with the Belgian Law of 8 December, 1992 
on the protection of privacy and the Belgian Law of 22 
August, 2002 on the rights of the patient.
Leuven is a medium-size city in the Dutch-speaking 
part of Belgium and has a population with a slightly 
lower ratio of ethnic minorities (EM) (15.4% in 2011) 
compared to the larger Belgian cities [11]. Of the overall 
Belgian adult population, 48% is overweight and 13% is 
obese (2013) [12]. The background prevalence of T2DM 
in Belgium is 6.5% [13]. UZ Leuven is one of the largest 
hospitals in the country. The out-patient diabetes center 
attends to about 4400 T2DM patients and 1400 type 1 
diabetes (T1DM) patients yearly. Patients are under the 
care of an experienced multidisciplinary team of endocri-
nologists, diabetes nurses, dieticians and psychologists. 
A well-structured electronic medical file, specifically 
designed for the diabetes center, is used for routine care.
Subjects who attended the diabetes center between 
2004 and 2014 were identified by the electronic medi-
cal database. A total of 9072 patients with diabetes were 
identified of whom 5968 had T2DM (65.8%), 1968 had 
T1DM (21.7%), 648 had secondary diabetes (7.1%), 140 
had gestational diabetes (1.5%), 239 had another type of 
diabetes (2.6%) and 69 patients had a metabolic syndrome 
(0.8%). To ensure that only patients with established 
T2DM were included, we excluded patients with only one 
contact labeled as T2DM between 2004 and 2014. Of the 
remaining 4557 patients with T2DM, 1077 patients were 
identified being younger than 45 years at the time of diag-
nosis. T2DM accounted for 13.1% of the diabetes popula-
tion <45 years attending our diabetes center in 2014. Due 
to suspicion of misdiagnosis, 86 files were evaluated in 
more detail and 54 patients were further excluded due to 
misclassification. Since the aim was also to assess the evo-
lution over time in this young-onset cohort, we retrieved 
details of the first and last visit in our center, ranging 
from 1998 to 2015. Another 137 patients were excluded 
because the follow-up time between the two visits was 
less than one year, leaving a young-onset T2DM cohort 
of 886 patients. To be able to compare the general char-
acteristics of the young-onset T2DM adults with T2DM 
patients diagnosed at an older age, we also retrospectively 
evaluated the records of 933 patients who attended UZ 
Leuven between 2004 and 2014 and who had been diag-
nosed with T2DM at an age between 60 and 70 years.
Outcomes were obtained from review of the elec-
tronic database. Clinical data recorded were gender, age, 
nationality, ethnicity, past history, length, weight, BMI 
(kg/m2), blood pressure (BP), diabetes duration, pres-
ence of diabetic retinopathy, smoking status, medication 
use and use of insulin. Biochemical data recorded were 
HbA1c, total cholesterol, LDL-cholesterol, triglycerides 
and microalbuminuria (defined as a urine albumin-cre-
atinin ratio >30 mg/g creatinin or a 24 h excretion of uri-
nary albumin of 31–299  mg or a urinary concentration 
of microalbumin of 21–199  mg/l). Cardiovascular risk 
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factors recorded were hypertension (systolic BP  ≥  140 
and/or diastolic BP  ≥  90  mmHg), overweight (BMI 
25–29.9  kg/m2) or obesity (BMI  ≥  30  kg/m2), nicotine 
use, LDL  ≥  70  mg/dl in secondary cardiovascular pre-
vention, LDL  ≥  100  mg/dl in primary cardiovascular 
prevention and a triglyceride level ≥150 mg/dl. The car-
diovascular complications recorded were carotid surgery, 
surgery of the lower limbs [thrombolysis, balloon dila-
tation, percutaneous transluminal arterioplasty (PTA) 
or an open vessel operation], transient ischemic attack 
(TIA) or cerebrovascular accident (CVA) and cardiac 
events [myocardial infarction or an intervention such as a 
percutaneous transluminal coronary angioplasty (PTCA) 
or a coronary artery bypass graft (CABG)]. When the file 
mentioned a diagnosis of ‘cardiac angina’ or ‘limb claudi-
cation’, it was analyzed in more detail to establish whether 
the patient had undergone an intervention or had a his-
tory of CVA or myocardial infarction. Furthermore, we 
analyzed the number of re-interventions, defined as 
new interventions following a previously conservative 
approach or a second TIA/CVA/cardiac event between 
the first and the last contact.
During the study time period, HbA1c was meas-
ured using different techniques. Between May 2002 
and August 2007, the immunoassay method Dimension 
HA1C of Dade Behring was used. From August 2007 
until October 2015, the reversed-phase cation-exchange 
chromatography was used (ADAMS HA-8160, Menar-
ini Diagnostics Benelux). Since October 2015, HbA1c 
has been measured by a high performance liquid chro-
matography principle with the cationic non-porous 
ion exchanger using the ionic difference (Tosoh HLC-
723G8, Tessenderlo, Belgium). Since 1996, reproduction 
of Hba1c complies with the National Glycohemoglobin 
Standardization Program [14]. During the entire period 
of the study, lipids and microalbuminuria were meas-
ured by the same biomedical technique with only a few 
changes in the calibration methods/equipment/assays. 
Total cholesterol was measured on Cobas 8000, Roche 
Diagnostics by enzymatic colorimetic CHOD-PAP 
method, triglycerides by enzymatic colorimetic GPO-
PAP method, HDL cholesterol by dextran sulfate/Mg 
precipitation followed by enzymatic colorimetric CHOD-
PAP reaction, calculated LDL-cholesterol by Friedewald 
formula (Total cholesterol—HDL cholesterol—Triglycer-
ides/4). Microalbuminuria was measured by an immuno-
turbidimetric method (Tina-Quant Albumin) on a Cobas 
8000 auto-analyzer from Roche Diagnostics.
Statistical analyses
Statistical analyses were performed using SPSS 23. Con-
tinuous variables were presented as mean and standard 
deviation if normally distributed and as median otherwise. 
Categorical variables were expressed as percentage. To 
compare variables between two groups, the independent 
t test or paired t test was used for normally distributed 
continuous variables, the Mann–Whitney’s U-test for non-
normally distributed continuous variables and the Chi 
squared test or McNemar test for categorical variables. 
For comparison of the occurrence of cardiovascular events 
between groups, logistic regression analysis was per-
formed to adjust for confounding factors such as smoking, 
HbA1c, BMI, LDL-cholesterol, systolic and diastolic blood 
pressure, diabetes duration, age and microalbuminuria. A 
p value of <0.05 (two-tailed) is considered significant.
Results
Characteristics of the young‑onset T2DM cohort at last 
contact
General characteristics
Of the 886 patients, mean age at diagnosis was 
37.3  ±  6.4  years, 44.1% were women and 12.1% (106) 
were from an EM background (32.0% Northern-Afri-
can, 29.2% black African, 19.8% Asian, 16.0% Middle-
Eastern and 2.8% South-American). Mean age at last 
contact was 57.3 ±  12.5  years and mean diabetes dura-
tion was 20.5 ± 11.8 years. Mean HbA1c was 7.3% ± 1.3 
(56  mmol/mol  ±  14) with 45.5% of patients reaching 
an HbA1c  <7.0% (52  mmol/mol) and 81.9% receiving 
insulin. Mean BMI was 31.2 ± 5.8 kg/m2, with 32.4% of 
patients being overweight and 56.8% being obese. Fur-
thermore, 16.6% of patients smoked, 49.9% were hyper-
tensive, 33.3% had elevated triglycerides and 34.1% did 
not reach the LDL cholesterol target. In addition, 81.7% 
of patients had at least two or more cardiovascular risk 
factors. By the time of the last contact, 0.9% of patients 
(8) had received carotid surgery, 6.9% of patients (61) 
had received vascular surgery of the lower limbs, 7.2% 
of patients (64) had experienced a CVA and 20.1% of 
patients (178) had suffered from a cardiac event. Diabetic 
retinopathy was present in 40.2% and microalbuminuria 
in 34.4% of patients.
Comparison between women and men
Table  1 gives an overview of the differences between 
women and men at the time of the last contact. Men were 
older at diagnosis (38.1 ± 5.8 vs. 36.4 ± 6.9, p < 0.0001), 
had a higher HbA1c [7.3% ± 1.4 (56 mmol/mol ± 15) vs. 
7.1% ±  1.2 (54 mmol/mol ±  13), p =  0.021], had lower 
rates of obesity (51.2 vs. 64.1%, p  <  0.0001) but higher 
rates of hypertension (53.4 vs. 45.3%, p  =  0.019) and 
smoked more often (20.2 vs. 12.0%, p = 0.001).
Comparison between Caucasians and EM patients
Compared to Caucasians, EM patients were 
younger at diagnosis (35.4  ±  6.8 vs. 37.6  ±  6.2  years, 
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Table 1 Characteristics and complications for men and women at last contact in the young-onset cohort
Data are mean ± SD, % or (number)
p values highlighted in italic are considered significant
EM ethnic minority; MF metformin with or without insulin; SU sulfonylureum with or without insulin; DPP-4 DPP-4-inhibitor; GLP-1 GLP-1-receptor-agonist; BMI body 
mass index; TG triglycerides; LDL LDL-cholesterol; CV cardiovascular; DRP diabetic retinopathy; TIA transient ischemic attack; CVA cerebrovascular accident; cardiac 
event a myocardial infarction or an intervention such as a percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
Men
N = 495 (55.9%)
Women
N = 391 (44.1%)
p value
% EM 12.4 11.7 0.762
Mean age at diagnosis 38.1 ± 5.8 36.4 ± 6.9 <0.0001
Mean age at last visit (years) 56.9 ± 11.5 57.8 ± 13.8 0.283
Mean follow-up (years) 8.1 ± 4.8 8.8 ± 5.1 0.029
Mean diabetes duration (years) 19.3 ± 11.0 22.0 ± 12.7 0.001
Mean HbA1c % (mmol/mol) 7.3 ± 1.4 (56 ± 15) 7.1 ± 1.2 (54 ± 13) 0.021
 % HbA1c ≥9% (74 mmol/mol) 13.7 8.0 0.008
 % Statin 79.6 70.8 0.006
Number of antihypertensive medications 0.177
 0 21.4 25.3
 1 18.4 15.3
 2 17.6 23.0
 ≥3 42.5 36.4
% Aspirin 58.6 55.5 0.356
% MF 53.1 55.5 0.483
% SU 1.4 1.8 0.656
% MF + SU 16.6 8.2 <0.0001
% Glitazones 0.2 0.5 0.431
% DPP-4 3.6 3.3 0.802
% GLP-1 10.9 5.1 0.002
% Insulin 79.8 84.7 0.062
% On 1 injection of insulin 5.3 5.6 0.807
% On 2 or 3 injections of insulin 5.9 8.2 0.175
% On multiple injections of insulin 68.7 70.8 0.488
Mean BMI (kg/m2) 30.5 ± 4.9 32.1 ± 6.7 <0.0001
 % Overweight 39.4 23.4 <0.0001
 % Obese 51.2 64.1 <0.0001
 % Hypertension 53.4 45.3 0.019
Mean TG 162.9 ± 175.7 135.6 ± 78.8 0.007
Mean LDL 74.1 ± 30.1 81.7 ± 31.2 <0.0001
 % High TG 35.7 30.1 0.093
 % LDL not on target in primary CV prevention 24.8 32.4 0.065
 % LDL not on target in secondary CV prevention 51.1 39.9 0.052
 % Smoking 20.2 12.0 0.001
 % ≥3 CV risk factors 59.4 50.1 0.006
 % DRP 40.3 40.1 0.942
 % Microalbuminuria 40.6 26.2 0.001
Mean age first CV event 53.4 ± 9.5 57.9 ± 10.1 <0.0001
 % New surgery lower limbs 3.0 (15) 2.0 (8)
 % New TIA/CVA 1.0 (5) 1.0 (4)
 % New cardiac event 4.8 (24) 3.1 (12)
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p  =  0.001), had a shorter diabetes duration at last 
visit (15.8  ±  10.6 vs. 21.2  ±  11.9  years, p  =  0.002) 
and were less often obese (43.3 vs. 55.6%, p  =  0.007) 
(Table 2).
Comparison between age of diagnosis <35 years and age 
at diagnosis between 35 and 45 years
Data were generally comparable between the two age 
groups, except for a lower proportion of men (48.6 vs. 
Table 2 Characteristics and complications for Caucasians and EM patients at last contact in the young-onset cohort
Data are mean ± SD, % or (number)
p values highlighted in italic are considered significant
EM ethnic minority, MF metformin with or without insulin; SU sulfonylureum with or without insulin; DPP-4 DPP-4-inhibitor; GLP-1 GLP-1-receptor-agonist; BMI body 
mass index; TG triglycerides; LDL LDL-cholesterol; CV cardiovascular; DRP diabetic retinopathy; TIA transient ischemic attack; CVA cerebrovascular accident; cardiac 
event a myocardial infarction or an intervention such as a percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
Caucasian
N = 769 (87.9%)
EM
N = 106 (12.1%)
p value
% Men 56.0 57.5 0.762
Mean age at diagnosis 37.6 ± 6.2 35.4 ± 6.8 0.001
Mean age at last visit (years) 58.4 ± 12.4 50.8 ± 11.7 <0.0001
Mean follow-up (years) 8.6 ± 4.9 7.0 ± 4.8 0.002
Mean diabetes duration (years) 21.2 ± 11.9 15.8 ± 10.6 0.002
Mean HbA1c % (mmol/mol) 7.3 ± 1.3 (56 ± 14) 7.4 ± 1.4 (57 ± 15) 0.461
 % Statin 78.1 59.4 <0.0001
Number of antihypertensive medications
 0 20.2 42.5 <0.0001
 1 16.3 23.6
 2 21.0 11.3
 ≥3 42.5 22.7
% MF 53.1 62.3 0.077
% SU 1.4 (11) 2.8 (3) 0.283
% MF + SU 12.9 11.3 0.649
% Glitazones 0.4 0 0.519
% DPP-4 2.9 (67) 7.5 (4) 0.013
% GLP-1 8.7 3.8 0.080
% Insulin 81.4 86.8 0.174
% On 1 injection of insulin 5.3 4.7 0.788
% On 2 or 3 injections of insulin 7.2 5.7 0.570
% On multiple injections of insulin 68.9 76.4 0.113
Mean BMI (kg/m2) 31.4 ± 5.9 29.8 ± 4.6 0.009
 % Overweight 28.8 44.3 0.002
 % Obese 55.6 43.3 0.007
 % Hypertension 48.7 43.4 0.269
Mean TG 151.7 ± 144.7 144.8 ± 132.7 0.660
Mean LDL 76.7 ± 31.0 82.8 ± 29.7 0.075
 % High TG 30.7 29.2 0.913
 % LDL not on target in primary CV prevention 27.2 30.9 0.472
 % LDL not on target in secondary CV prevention 45.2
 % Smoking 17.2 12.3 0.201
 % ≥3 CV risk factors 56.6 45.3 0.027
 % DRP 40.8 40.4 0.950
 % Microalbuminuria 35.1 32.1 0.667
 % New surgery lower limbs 3.0 (23) 0 (0)
 % New TIA/CVA 1.0 (8) 0.9 (1)
 % New cardiac event 4.3 (33) 2.8 (3)
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58.7%, p  =  0.006), less frequent use of statins (65.5 vs. 
79.9%, p  <  0.0001) and anti-hypertensive medication 
(p < 0.0001), more frequent use of insulin (88 vs. 79.6%, 
p =  0.004) and a higher LDL-cholesterol (84.6 ±  34 vs. 
74.7 ± 29, p < 0.0001) in the group with age of diagno-
sis <35 years compared to the group diagnosed at an age 
between 35 and 45 years.
Cardiovascular events at last visit in the different subgroups 
in the young‑onset T2DM cohort
In the unadjusted analyses, there were statistically sig-
nificant more cardiac events in men, Caucasians and the 
group with age at diagnosis between 35 and 45  years. 
However, after adjustment for confounders such as smok-
ing, HbA1c, BMI, LDL-cholesterol, systolic and diastolic 
BP, diabetes duration, age and microalbuminuria, rates of 
cardiac events remained only significantly higher in men 
compared to women (24.3 vs. 14.8%, p = 0.010) (Table 3).
Comparison between the first and last visit of the 
young‑onset T2DM cohort
Compared to the first visit, by the time of the last visit, 
glycemic control had improved [7.3%  ±  1.3 (56  mmol/
mol  ±  14) vs. 7.9%  ±  1.7 (62  mmol/mol  ±  19), 
p  <  0.0001] in line with more use of oral antidiabetic 
drugs (OAD) and insulin (81.9 vs. 36.9%, p  <  0.0001) 
(Table  4). Furthermore, BMI decreased (31.2  ±  5.8 
vs. 31.7 ±  5.8, p =  0.009), there was a lower LDL-cho-
lesterol (77.9  ±  31.1 vs. 107.3  ±  37.4, p  <  0.0001) and 
less hypertension (49.9 vs. 55.6%, p  =  0.018). At last 
contact, the rate of cardiovascular events increased 
(37.8 vs. 21.6%, p  <  0.0001). Over a mean follow-up of 
8.4 ±  4.9  years, 2.6% (23) of patients underwent a sec-
ond surgery of the lower limbs, 1.0% (9) had a new CVA 
and 4.1% (36) had a new myocardial infarction or cardiac 
intervention (Table 4).
Comparison of characteristics between the young‑ 
and old‑onset T2DM cohorts at last contact
Compared to the old-onset T2DM cohort, patients with 
young-onset T2DM had a higher HbA1c [7.3  ±  1.3% 
(56 mmol/mol ± 14) vs. 6.9 ± 1.0% (51 mmol/mol ± 11), 
p  <  0.0001] and smoked more often (16.6 vs. 7.0%, 
p  =  <0.0001). When adjusted for confounders (smok-
ing, HbA1c, BMI, LDL-cholesterol, systolic and diastolic 
BP, age, diabetes duration and microalbuminuria), there 
was no difference in cardiovascular events between both 
groups (Table 5).
Discussion
This study on a large Belgian cohort of adults diag-
nosed with T2DM  <45  years provides insight in the 
general characteristics, complications and current care 
of this high-risk population. This study demonstrates 
that, despite a relatively young age at the last follow-up 
visit, young-onset T2DM patients have a high-risk phe-
notype and have a high life-time risk for cardiovascular 
complications.
Table 3 Overview of the cardiovascular events at last contact in the different young-onset T2DM subgroups
Data are % or (number)
p values highlighted in italic are considered significant
TIA transient ischemic attack; CVA cerebrovascular accident; CV cardiovascular; EM ethnic minority; cardiac event a myocardial infarction or an intervention such as a 
percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
Carotid surgery Surgery lower limbs TIA/CVA Cardiac event CV event
Men vs. women
 % Men 0.8 (4) 8.3 (41) 8.5 (42) 24.3 (120) 41.4 (205)
 % Women 1.0 (4) 5.1 (20) 5.6 (22) 14.8 (58) 33.2 (130)
p value 0.737 0.064 0.103 <0.0001 0.013
Adjusted p value 0.938 0.154 0.149 0.010 0.014
Caucasian vs. EM
 % Caucasians 1.0 (8) 7.7 (59) 7.9 (61) 21.6 (166) 40.8 (313)
 % EM 0 (0) 1.9 (2) 2.8 (3) 10.4 (11) 17.9 (19)
 p value 0.291 0.028 0.058 0.0008 <0.0001
 Adjusted p value 1.000 0.845 0.998 0.960 0.926
Different age groups at diagnosis
 % Diagnosis <35 years 0.8 (2) 6.4 (16) 3.6 (9) 15.7 (39) 26.9 (67)
 % Diagnosis 35–45 years 0.9 (6) 7.1 (45) 8.6 (55) 21.9 (139) 42.1 (268)
 p value 0.844 0.736 0.009 0.038 <0.0001
 Adjusted p value 0.996 0.566 0.744 0.651 0.189
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In our young-onset T2DM cohort, 81.7% of patients 
had at least two cardiovascular risk factors at the last 
follow-up, a finding which is in agreement with the 
SEARCH study where 92% of T2DM patients had at 
least two cardiovascular risk factors [15]. Obesity is one 
of the main driving factors for the increase in prevalence 
of young-onset T2DM [1, 3]. Of our entire young-onset 
T2DM cohort, 32.4% of patients were overweight and 
56.8% were obese. Compared to the first visit at our 
center, patients’ metabolic control improved signifi-
cantly over time, but the frequency of cardiovascular 
risk factors remained high. This confirms the high-risk 
Table 4 Characteristics and complications for the first and last visit of the young-onset T2DM cohort
Data are mean ± SD, % or (number)
p values highlighted in italic are considered significant
MF metformin with or without insulin; SU sulfonylureum with or without insulin; DPP-4 DPP-4-inhibitor; GLP-1 GLP-1-receptor-agonist; BMI body mass index; TG 
triglycerides; LDL LDL-cholesterol; CV cardiovascular; DRP diabetic retinopathy; TIA transient ischemic attack; CVA cerebrovascular accident; cardiac event a myocardial 
infarction or an intervention such as a percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
First contact
N = 886
Last contact
N = 886
p value
Mean age at contacts 48.9 ± 11.5 57.3 ± 12.5 <0.0001
Mean diabetes duration (years) 12.1 ± 10.7 20.5 ± 11.8 <0.0001
Mean HbA1c % (mmol/mol) 7.9 ± 1.7 (62 ± 19) 7.3 ± 1.3 (56 ± 14) <0.0001
 % HbA1c ≥7% (52 mmol/mol) 66 54.5 <0.0001
 % Statin 32.2 75.7 <0.0001
Number of antihypertensive medications <0.0001
 0 44.9% 23.1%
 1 21.7% 17.0%
 2 17.7% 20.0%
 ≥3 15.8% 39.7%
% MF 30.9 54.2 <0.0001
% SU 5.5 1.6 <0.0001
% MF + SU 20.0 12.9 <0.0001
% DPP-4 1.7 3.5 0.014
% GLP-1 1.2 8.4 <0.0001
% Insulin 36.9 81.9 <0.0001
% On 1 injection of insulin 7.4 5.4 0.054
% On 2 or 3 injections of insulin 12.5 6.9 <0.0001
% On multiple injections of insulin 16.9 69.6 <0.0001
Mean BMI (kg/m2) 31.7 ± 5.8 31.2 ± 5.8 0.009
 % Hypertension 55.6 49.9 0.018
Mean TG 192.5 ± 217.2 152.0 ± 144.4 <0.0001
Mean LDL 107.3 ± 37.4 77.9 ± 31.1 <0.0001
 % LDL not on target in primary CV prevention 58.3 27.7 <0.0001
 % LDL not on target in secondary CV prevention 78.7 44.8 <0.0001
 % Smoking 17.2 16.6 0.709
 % ≥2 CV risk factors 87.6 81.7 <0.0001
 % DRP 27.2 40.2 <0.0001
 % Microalbuminuria 28.1 34.4 0.003
 % Carotid surgery 0.7 (6) 0.9 (8) 0.500
 % Surgery lower limbs 3.7 (33) 6.9 (61) <0.0001
 % TIA/CVA 3.6 (32) 7.2 (64) <0.0001
 % Cardiac event 12.8 (113) 20.1 (178) <0.0001
 % CV event (peripheral; heart) 21.6 (191) 37.8 (335) <0.0001
 % New surgery lower limbs 2.6 (23)
 % New TIA/CVA 1.0 (9)
 % New cardiovascular event 4.1 (36)
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cardiovascular phenotype, as seen in other populations 
with young-onset T2DM [5, 8, 15–17]. The high preva-
lence of cardiovascular risk factors is alarming, since 
mortality in people with T2DM is mainly driven by car-
diovascular disease and the incidence of macrovascu-
lar events increases with disease duration [1]. Early and 
aggressive risk factor management is therefore man-
datory, but this is often very challenging to achieve as 
seen in our study [18, 19]. Cardiovascular risk factors 
remained often insufficiently controlled despite the fre-
quent use of statins and antihypertensive medication in 
our population.
Data on long-term cardiovascular follow-up and mor-
tality are limited in this population, in part because 
young-onset T2DM is a relatively new occurrence in 
European populations. A 9-year follow-up study of a very 
high-risk population of 69 First Nation Canadians ado-
lescents with T2DM showed a mortality rate of 9% [20]. 
Our data confirm a high rate of cardiovascular compli-
cations in young-onset T2DM at a relatively young age, 
with 6.9% having received vascular surgery of the lower 
limbs, 7.2% having experienced a CVA and 20.1% hav-
ing had a myocardial infarction or cardiac surgery by the 
time of the last follow-up visit. In our study, the rate of 
cardiac events remained significantly higher in men com-
pared to women after adjustment for confounders. This 
is in contrast with findings of Hillier et al. [10] showing 
that the increased relative risk for myocardial infarction 
in young adults almost entirely occurred in women. This 
difference may be due to the fact that this study looked 
at complications emerging within 4 years after diagnosis 
in an American population, while our European study 
registered all cardiac events within a mean diabetes dura-
tion of 20.5 years which allowed sufficient time for those 
complications to occur. Studies from a large diabetes 
center in Sheffield in the UK demonstrated that diabe-
tes duration was a significant predictor for microvascu-
lar and cardiovascular complications in young adults 
with T2DM, while age of diagnosis did not appear to be 
an important factor [9]. This is in line with the present 
study, since after adjustment for diabetes duration, age 
and cardiovascular risk factors, there was no difference 
in the rate of cardiovascular events between young-onset 
and old-onset diabetes patients. This would suggest that 
the more aggressive phenotype in young-onset T2DM is 
mostly due to the longer diabetes duration, with a com-
parable complication burden occurring at an earlier age 
[9]. However, this is in contrast with the data of Hillier 
Table 5 Comparison of characteristics and complications between the young- and old-onset T2DM cohorts at last contact
Data are mean ± SD or %
p values highlighted in italic are considered significant
BMI body mass index; TG triglycerides; LDL LDL-cholesterol; DRP diabetic retinopathy; TIA transient ischemic attack; CVA cerebrovascular accident; cardiac event a 
myocardial infarction or an intervention such as a percutaneous transluminal coronary angioplasty or a coronary artery bypass graft
Age at diagnosis <45 years
N = 886
Age at diagnosis 60–70 years
N = 933
p value Adjusted p value
% Men 55.9 53.2 0.246
% Belgian nationality 91.3 97.2 0.024
Mean age at last visit (years) 57.3 ± 12.6 75.7 ± 6.8 <0.0001
Median age at diagnosis (years) 39.0 (8;45) 64.1 (60;70) <0.0001
Median follow-up (years) 7.6 (0;17) 4.6 (1;17) <0.0001
Mean diabetes duration (years) 20.5 ± 11.8 11.9 ± 6.6 <0.0001
Mean HbA1c % (mmol/mol) 7.3 ± 1.3 (56 ± 14) 6.9 ± 1.0 (51 ± 11) <0.0001
Mean BMI (kg/m2) 31.2 ± 5.8 29.6 ± 5.5 <0.0001
 % Overweight 32.4 38.3 0.011
 % Obese 56.8 42.0 <0.0001
 % Hypertension 49.9 50.2 0.905
Median TG 118.5 (25;2837) 118.0 (24;706) 0.829
Mean LDL 77.5 ± 30.9 75.2 ± 29.4 0.163
 % Smoking 16.6 7.0 <0.0001
 % DRP 40.2 23.7 <0.0001
 % Microalbuminuria 34.4 34.0 0.915
 % Carotid surgery 0.9 (8) 4.3 (40) <0.0001 0.843
 % Surgery lower limbs 6.9 (61) 10.5 (98) 0.006 0.327
 % TIA/CVA 7.2 (64) 16.1 (150) <0.0001 0.739
 % Cardiac event 20.1 (178) 31.8 (297) <0.0001 0.386
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et  al. [1] showing that already at the time of diagnosis, 
adults with young-onset T2DM were more obese and 
had slightly worse glycemic control than the old-onset 
group. Furthermore, after controlling for length of fol-
low-up (this equals diabetes duration since the study only 
included patients newly diagnosed with T2DM) young-
onset T2DM patients had a 14-fold higher overall hazard 
of developing myocardial infarction compared to control 
subjects, while this was only a fourfold increased hazard 
in the old-onset T2DM group [10]. These data would 
therefore rather support the hypothesis that young-onset 
T2DM builds on a somewhat different pathogenesis 
(such as a more rapid decline in beta cell function and 
fructose in soft drinks increasing insulin resistance, low-
ering HDL and increasing triglycerides) resulting in an 
inherently more aggressive phenotype [2, 7, 9].
Achieving and maintaining good glycemic control 
seems to be more difficult in this young-onset T2DM 
population [9, 10, 18, 21]. In our cohort, glycemic con-
trol improved significantly over time, but more than half 
of patients still had an HbA1c above target at the last 
contact, despite 81.9% receiving insulin. This may be 
related to the fact that diagnosing diabetes mellitus at a 
younger age is associated with poor treatment adherence 
by patients and less aggressive treatment by health care 
professionals [9, 10, 18, 21]. However, there is few data 
to guide treatment of T2DM in youth. The ‘Treatment 
Options for type 2 Diabetes in Adolescents and Youth’ 
(TODAY) study was designed to compare the efficacy of 
three treatment regimens (metformin alone, metformin 
plus rosiglitazone and metformin plus intensive lifestyle 
modification) to achieve durable glycemic control in 
young-onset T2DM [19]. However, failure rates for all 
treatment arms were high [19].
In contrast to other series of T2DM in youth [3], there 
was a male predominance of T2DM in this cohort. Com-
pared to women at their last visit, men had worse glyce-
mic control despite a shorter diabetes duration. Although 
there was no significant difference in the frequency of 
insulin use, insulin might have been initiated earlier in 
women of childbearing age. Furthermore, men had more 
often at least three cardiovascular risk factors. In con-
trast, LDL-cholesterol was lower in men, probably due 
to the greater statin use compared to women. This might 
be related to the potential teratogenic effect of statins in 
women of childbearing age. These findings are in contrast 
with a recent study from two large diabetes centers in the 
UK showing equally prevalent risk factors between men 
and women [8].
An EM background is a known risk factor for the 
development of T2DM at a younger age. In particular, 
Japanese, Hispanic and Native American patients carry 
the highest risk of developing T2DM in childhood [5, 6]. 
In our cohort, 12.1% of patients had an EM background, 
which is in line with the frequency of EM in the back-
ground Belgian population [11]. In our cohort, the EM 
group had a similar metabolic control as the Caucasian 
population and were more often overweight but less 
often obese. This is in contrast with many studies show-
ing that obesity disproportionally affects minorities [22]. 
This is probably due to the small absolute number of EM 
patients in our cohort.
Different studies report variable rates of microvascu-
lar complications in young-onset T2DM, probably due 
to differences in subjects’ age and disease duration [23]. 
A population-based cohort study in Sweden found simi-
lar rates of retinopathy between the T2DM and T1DM 
groups but the incidence of severe retinopathy was sig-
nificantly higher in younger adults aged 15–34 years with 
T2DM compared with T1DM both at the time of diag-
nosis and after 10 years of follow-up [24]. In our cohort, 
40.2% of patients had diabetic retinopathy at their last 
visit, with a high screening rate (91%). The prevalence of 
microalbuminuria at last visit in our young-onset popula-
tion was 34.4%. This is comparable to data of Hillier et al. 
showing that about one in four adults developed incident 
microalbuminuria during follow-up, with similar findings 
in the young-onset group versus the usual-onset group. 
However, when adjusted for gender and length of follow-
up, adults with young-onset T2DM had a 20% increased 
hazard of developing microalbuminuria compared to the 
usual-onset group [10].
The strengths of our study are the detailed analysis of 
a large cohort of young-onset T2DM patients and long-
term follow-up data on cardiovascular complications. 
Limitations are the retrospective nature of the analy-
sis, the lack of data on mortality and the fact that the 
first visit in our center was often many years after the 
diagnosis. Furthermore, this study is based on special-
ist care populations and the results might therefore not 
be extrapolated to patients followed in primary care. 
Another limitation is the use of different methods for 
data extraction concerning microalbuminuria and dia-
betic retinopathy in the young- versus old-onset T2DM 
groups.
Conclusions
In conclusion, this study shows that young-onset T2DM 
is a prevalent condition with often insufficient metabolic 
control. Young-onset T2DM patients have a high rate of 
cardiovascular complications at a relatively young age. In 
our cohort, especially men were at a high risk for a car-
diac event. Therefore, there is need for tailored treatment 
strategies to better manage this high-risk group. More 
research is also required to better understand how the 
pathophysiology of T2DM differs by the age of onset.
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